Meta-analysis of the association between N-methyl-d-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder

Schizophrenia Research

Volumn 157, Issue 1-3, 2014, Pages 249-258

  Pearlman, Daniel M ^a,b   Najjar, Souhel ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

Author keywords

Antibodies; Bipolar disorder; Immunoglobulin; Major depressive disorder; Meta analysis; N methyl d aspartate receptor; Psychoimmunology; Schizoaffective disorder; Schizophrenia; Systematic review

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1 ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ACUTE DISEASE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; BIPOLAR DISORDER; CASE CONTROL STUDY; CELL ASSAY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK PATIENT; HUMAN; MAJOR DEPRESSION; MANIA; META ANALYSIS (TOPIC); N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW; BLOOD; IMMUNOLOGY; META ANALYSIS; PSYCHOSIS;

AUTOANTIBODIES; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84904132951     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.05.001     Document Type: Review

References (70)

1. Arinuma Y., Yanagida T., Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2008, 58(4):1130-1135.
2. Armangue T., Leypoldt F., Malaga I., Raspall-Chaure M., Marti I., Nichter C., et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann. Neurol. 2014, 75(2):317-323.
3. Bechter K., Reiber H., Herzog S., Fuchs D., Tumani H., Maxeiner H.G. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J. Psychiatr. Res. 2010, 44(5):321-330.
4. Benros M.E., Nielsen P.R., Nordentoft M., Eaton W.W., Dalton S.O., Mortensen P.B. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry 2011, 168(12):1303-1310.
5. Benros M.E., Waltoft B.L., Nordentoft M., Ostergaard S.D., Eaton W.W., Krogh J., et al. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry 2013, 70(8):812-820.
6. Benros M.E., Eaton W.W., Mortensen P.B. The epidemiologic evidence linking autoimmune diseases and psychosis. Biol. Psychiatry 2014, 75(4):300-306.
7. Benros M.E., Pedersen M.G., Rasmussen H., Eaton W.W., Nordentoft M., Mortensen P.B. A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. Am. J. Psychiatry 2014, 171(2):218-226.
8. Bokesch P.M., Izykenova G.A., Justice J.B., Easley K.A., Dambinova S.A. NMDA receptor antibodies predict adverse neurological outcome after cardiac surgery in high-risk patients. Stroke 2006, 37(6):1432-1436.
9. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 2010, 167(3):261-280.
10. Brown A.S., Schaefer C.A., Quesenberry C.P., Liu L., Babulas V.P., Susser E.S. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am. J. Psychiatry 2005, 162(4):767-773.
11. Buka S.L., Tsuang M.T., Torrey E.F., Klebanoff M.A., Bernstein D., Yolken R.H. Maternal infections and subsequent psychosis among offspring. Arch. Gen. Psychiatry 2001, 58(11):1032-1037.
12. Buka S.L., Cannon T.D., Torrey E.F., Yolken R.H. Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol. Psychiatry 2008, 63(8):809-815. Collaborative Study Group on the Perinatal Origins of Severe Psychiatric, D.
13. Chen S.J., Chao Y.L., Chen C.Y., Chang C.M., Wu E.C., Wu C.S., et al. Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. Br. J. Psychiatry 2012, 200(5):374-380.
14. Choe C.U., Karamatskos E., Schattling B., Leypoldt F., Liuzzi G., Gerloff C., et al. A clinical and neurobiological case of IgM NMDA receptor antibody associated encephalitis mimicking bipolar disorder. Psychiatry Res. 2013, 208(2):194-196.
15. Dalmau J., Gleichman A.J., Hughes E.G., Rossi J.E., Peng X., Lai M., et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008, 7(12):1091-1098.
16. Dambinova S.A., Khounteev G.A., Izykenova G.A., Zavolokov I.G., Ilyukhina A.Y., Skoromets A.A. Blood test detecting autoantibodies to N-methyl-d-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin. Chem. 2003, 49(10):1752-1762.
17. Dambinova S.A., Bettermann K., Glynn T., Tews M., Olson D., Weissman J.D., et al. Diagnostic potential of the NMDA receptor peptide assay for acute ischemic stroke. PLoS One 2012, 7(7):e42362.
18. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7(3):177-188.
19. Dickerson F., Stallings C., Vaughan C., Origoni A., Khushalani S., Yolken R. Antibodies to the glutamate receptor in mania. Bipolar Disord. 2012, 14(5):547-553.
20. Dickerson F., Stallings C., Origoni A., Vaughan C., Katsafanas E., Khushalani S., et al. A combined marker of inflammation in individuals with mania. PLoS One 2013, 8(9):e73520.
21. Dickerson F., Stallings C., Origoni A., Vaughan C., Katsafanas E., Khushalani S., et al. Antibodies to Toxoplasma gondii in individuals with mania. Bipolar Disord. 2014, 16(2):129-136.
22. Eaton W.W., Byrne M., Ewald H., Mors O., Chen C.Y., Agerbo E., et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am. J. Psychiatry 2006, 163(3):521-528.
23. Eaton W.W., Pedersen M.G., Nielsen P.R., Mortensen P.B. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010, 12(6):638-646.
24. Ezeoke A., Mellor A., Buckley P., Miller B. A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr. Res. 2013, 150(1):245-251.
25. Faust T.W., Chang E.H., Kowal C., Berlin R., Gazaryan I.G., Bertini E., et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(43):18569-18574.
26. Gilvarry C.M., Sham P.C., Jones P.B., Cannon M., Wright P., Lewis S.W., et al. Family history of autoimmune diseases in psychosis. Schizophr. Res. 1996, 19(1):33-40.
27. Gleichman A.J., Spruce L.A., Dalmau J., Seeholzer S.H., Lynch D.R. Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J. Neurosci. 2012, 32(32):11082-11094.
28. Gono T., Kawaguchi Y., Kaneko H., Nishimura K., Hanaoka M., Kataoka S., et al. Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford) 2011, 50(9):1578-1585.
29. Govorin N.V., Vasil'eva A.I. Effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia. Zh. Nevropatol. Psikhiatr. Im. S. S. Korsakova 2011, 111(3):54-57.
30. Hammer C., Stepniak B., Schneider A., Papiol S., Tantra M., Begemann M., et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol. Psychiatry 2013 Sep 3, [Epub ahead of print] PubMed PMID: 23999527. 10.1038/mp.2013.110.
31. Haussleiter I.S., Emons B., Schaub M., Borowski K., Brune M., Wandinger K.P., et al. Investigation of antibodies against synaptic proteins in a cross-sectional cohort of psychotic patients. Schizophr. Res. 2012, 140(1-3):258-259.
32. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
33. Hughes E.G., Peng X., Gleichman A.J., Lai M., Zhou L., Tsou R., et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J. Neurosci. 2010, 30(17):5866-5875.
34. International Schizophrenia C., Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460(7256):748-752.
35. Irani S.R., Bera K., Waters P., Zuliani L., Maxwell S., Zandi M.S., et al. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010, 133(Pt 6):1655-1667.
36. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20(3):201-225.
37. Kayser M.S., Titulaer M.J., Gresa-Arribas N., Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2013, 70(9):1133-1139.
38. Lapteva L., Nowak M., Yarboro C.H., Takada K., Roebuck-Spencer T., Weickert T., et al. Anti-N-methyl-d-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 2006, 54(8):2505-2514.
39. Lauvsnes M.B., Omdal R. Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. J. Neurol. 2012, 259(4):622-629.
40. Lauvsnes M.B., Maroni S.S., Appenzeller S., Beyer M.K., Greve O.J., Kvaloy J.T., et al. Memory dysfunction in primary Sjogren's syndrome is associated with anti-NR2 antibodies. Arthritis Rheum. 2013, 65(12):3209-3217.
41. Lennox B., Zandi M., Irani S., Coles A.J., Vincent A. Anti-GAD65, NMDAR and VGKC antibodies detected in first episode psychosis. Schizophr. Bull. 2009, 35(suppl 1):3.
42. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329(5994):959-964.
43. Masdeu J.C., Gonzalez-Pinto A., Matute C., Ruiz De Azua S., Palomino A., De Leon J., et al. Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. Am. J. Psychiatry 2012, 169(10):1120-1121.
44. Mortensen P.B., Norgaard-Pedersen B., Waltoft B.L., Sorensen T.L., Hougaard D., Torrey E.F., et al. Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth. Biol. Psychiatry 2007, 61(5):688-693.
45. Najjar S., Pearlman D.M., Alper K., Najjar A., Devinsky O. Neuroinflammation and psychiatric illness. J. Neuroinflammation 2013, 10:43.
46. Najjar S., Pearlman D.M., Hirsch S., Friedman K., Strange J., Reidy J., et al. Brain biopsy findings link major depressive disorder to neuroinflammation, oxidative stress, and neurovascular dysfunction: A case report. Biol. Psychiatry 2013 Sep 13, pii: S0006-3223(13)00741-5. http://dx.doi.org/10.1016j.biopsych.2013.07.041 [Epub ahead of print] PubMed PMID: 24075735.
47. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52(12):998-1007.
48. Omdal R., Brokstad K., Waterloo K., Koldingsnes W., Jonsson R., Mellgren S.I. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol. 2005, 12(5):392-398.
49. Paoletti P., Bellone C., Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 2013, 14(6):383-400.
50. Pollak T.A., McCormack R., Peakman M., Nicholson T.R., David A.S. Prevalence of anti-N-methyl-d-aspartate (NMDA) antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol. Med. 2013, 1-13.
51. Prüss H., Finke C., Holtje M., Hofmann J., Klingbeil C., Probst C., et al. N-methyl-d-aspartate receptor antibodies in herpes simplex encephalitis. Ann. Neurol. 2012, 72(6):902-911.
52. Pruss H., Holtje M., Maier N., Gomez A., Buchert R., Harms L., et al. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 2012, 78(22):1743-1753.
53. Pruss H., Holtje M., Maier N., Gomez A., Buchert R., Harms L., et al. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 2012, 1743-1753. (United States).
54. Rhoads J., Guirgis H., McKnight C., Duchemin A.M. Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schizophrenia. Schizophr. Res. 2011, 129(2-3):213-214.
55. Schwartz M., Kormilachev M., Kushnir M., Weller B., Rochas M., Toubi E. Lupus anticoagulant and anticardiolipin antibodies in serum of patients treated with risperidone. J. Clin. Psychiatry 2009, 70(5):769-771.
56. Shalev H., Serlin Y., Friedman A. Breaching the blood-brain barrier as a gate to psychiatric disorder. Cardiovasc. Psychiatry Neurol. 2009, 2009:278531.
57. Shen H., Li R., Xiao H., Zhou Q., Cui Q., Chen J. Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. J. Psychiatr. Res. 2009, 43(6):615-619.
58. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460(7256):753-757.
59. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460(7256):744-747.
60. Steiner J., Walter M., Glanz W., Sarnyai Z., Bernstein H.G., Vielhaber S., et al. Increased prevalence of diverse N-methyl-d-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-d-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013, 70(3):271-278.
61. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283(15):2008-2012.
62. Torrey E.F., Miller J., Rawlings R., Yolken R.H. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr. Res. 1997, 28(1):1-38.
63. Torrey E.F., Bartko J.J., Lun Z.R., Yolken R.H. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2007, 33(3):729-736.
64. Tsutsui K., Kanbayashi T., Tanaka K., Boku S., Ito W., Tokunaga J., et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 2012, 12:37.
65. von Engelhardt J., Doganci B., Seeburg P.H., Monyer H. Synaptic NR2A - but not NR2B-Containing NMDA receptors increase with blockade of ionotropic glutamate receptors. Front. Mol. Neurosci. 2009, 2:19.
66. Walters J.T., Rujescu D., Franke B., Giegling I., Vasquez A.A., Hargreaves A., et al. The role of the major histocompatibility complex region in cognition and brain structure: a schizophrenia GWAS follow-up. Am. J. Psychiatry 2013, 170(8):877-885.
67. Yolken R.H., Torrey E.F. Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev. 1995, 8(1):131-145.
68. Yoshio T., Okamoto H., Hirohata S., Minota S. IgG anti-NR2 glutamate receptor autoantibodies from patients with systemic lupus erythematosus activate endothelial cells. Arthritis Rheum. 2013, 65(2):457-463.
69. Zandi M.S., Irani S.R., Lang B., Waters P., Jones P.B., McKenna P., et al. Disease-relevant autoantibodies in first episode schizophrenia. J. Neurol. 2011, 258(4):686-688.
70. Zheng S., Eacker S.M., Hong S.J., Gronostajski R.M., Dawson T.M., Dawson V.L. NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. J. Clin. Invest. 2010, 120(7):2446-2456.